Core Viewpoint - CStone Pharmaceuticals' subsidiary, Demei Pharmaceuticals, received approval from the National Medical Products Administration for the new drug application of phosphoric acid lucotini cream for vitiligo on January 30 [1] Financial Projections - The company maintains its profit forecast for 2025 at 1.74 billion yuan, reflecting confidence in future earnings [1] - The profit forecast for 2026 has been raised by 5% to 1.98 billion yuan due to incremental revenue from the new product [1] - A new profit forecast for 2027 has been introduced at 2.42 billion yuan, indicating expected growth [1] Rating and Target Price - The company maintains a "outperforming the industry" rating for CStone Pharmaceuticals [1] - The target price has been increased by 7% to 16.5 HKD, reflecting positive market sentiment [1]
研报掘金丨中金：上调康哲药业目标价至16.5港元，维持“跑赢行业”评级